Rafferty Asset Management
EBS icon

Rafferty Asset Management’s Emergent Biosolutions EBS Stock Holding History

Rafferty Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Sell
47,430
-37,769
-44% -$316K ﹤0.01% 952
2026
Q1 		$707K Sell
85,199
-3,819
-4% -$39.6K ﹤0.01% 846
2025
Q4 		$1.1M Sell
89,018
-5,203
-6% -$55.8K ﹤0.01% 780
2025
Q3 		$831K Buy
94,221
+16,314
+21% +$127K ﹤0.01% 831
2025
Q2 		$497K Sell
77,907
-33,193
-30% -$190K ﹤0.01% 890
2025
Q1 		$540K Sell
111,100
-33,620
-23% -$278K ﹤0.01% 850
2024
Q4 		$1.38M Buy
144,720
+699
+0.5% +$6.41K ﹤0.01% 734
2024
Q3 		$1.2M Buy
+144,021
New +$1.31M ﹤0.01% 761
2023
Q3 		– Sell
-581,625
Closed -$4.27M – 1082
2023
Q2 		$4.27M Buy
581,625
+198,538
+52% +$1.84M 0.02% 452
2023
Q1 		$3.97M Sell
383,087
-32,505
-8% -$393K 0.03% 434
2022
Q4 		$4.91M Buy
415,592
+180,609
+77% +$2.79M 0.04% 377
2022
Q3 		$4.93M Buy
234,983
+107,256
+84% +$2.98M 0.05% 340
2022
Q2 		$3.96M Sell
127,727
-18,901
-13% -$645K 0.04% 330
2022
Q1 		$6.02M Buy
146,628
+14,963
+11% +$660K 0.04% 328
2021
Q4 		$5.72M Buy
131,665
+77,075
+141% +$3.49M 0.03% 328
2021
Q3 		$2.73M Buy
54,590
+13,520
+33% +$819K 0.02% 534
2021
Q2 		$2.59M Buy
41,070
+4,124
+11% +$265K 0.02% 582
2021
Q1 		$3.43M Buy
36,946
+25,807
+232% +$2.64M 0.02% 399
2020
Q4 		$998K Sell
11,139
-9,092
-45% -$834K 0.01% 494
2020
Q3 		$2.09M Buy
20,231
+3,754
+23% +$405K 0.03% 400
2020
Q2 		$1.3M Buy
16,477
+11,820
+254% +$881K 0.02% 472
2020
Q1 		$269K Sell
4,657
-34,943
-88% -$2.01M 0.01% 465
2019
Q4 		$2.14M Sell
39,600
-14,963
-27% -$812K 0.03% 366
2019
Q3 		$2.85M Sell
54,563
-51,835
-49% -$2.41M 0.04% 241
2019
Q2 		$5.14M Buy
106,398
+26,947
+34% +$1.29M 0.09% 159
2019
Q1 		$4.01M Buy
+79,451
New +$4.69M 0.06% 170

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Rafferty Asset Management's EBS Position: Q2 2026 in Review

Rafferty Asset Management reduced its Emergent Biosolutions (EBS) stake by 44% in Q2 2026, selling an estimated $316K and leaving 47,430 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #952.

Rafferty Asset Management first reported a position in EBS in Q1 2019 and has held it in 26 quarters since. The position peaked at $6.02M in Q1 2022. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Rafferty Asset Management held 47,430 shares of Emergent Biosolutions worth $397K as of Q2 2026.
  • Rafferty Asset Management sold 37,769 Emergent Biosolutions shares in Q2 2026, an estimated $316K.
  • Emergent Biosolutions made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #952 holding.
  • Rafferty Asset Management first reported a position in Emergent Biosolutions in Q1 2019 and has held it in 26 quarters since.
  • Rafferty Asset Management's Emergent Biosolutions position peaked at $6.02M in Q1 2022.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.